[{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"NINDS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"SB-0110","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Sinopia Biosciences \/ NINDS","highestDevelopmentStatusID":"4","companyTruncated":"Sinopia Biosciences \/ NINDS"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"MJFF","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"SB-0110","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Sinopia Biosciences \/ MJFF","highestDevelopmentStatusID":"4","companyTruncated":"Sinopia Biosciences \/ MJFF"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"National Institute of General Medical Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sinopia Biosciences \/ National Institute of General Medical Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Sinopia Biosciences \/ National Institute of General Medical Sciences"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"NIDCR","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Sinopia Biosciences \/ NIDCR","highestDevelopmentStatusID":"12","companyTruncated":"Sinopia Biosciences \/ NIDCR"}]

Find Clinical Drug Pipeline Developments & Deals by Sinopia Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The funding aims to support the company in discovering novel small molecules and identifying promising treatment candidates for oral mucositis.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 12, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery

                          Sponsor : NIDCR

                          Deal Size : $2.2 million

                          Deal Type : Funding

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The proceeds will advance its computational drug discovery LEarn And DiScover (LEADSâ„¢) platform and explore applications in oncology and immunology.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 30, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : National Institute of General Medical Sciences

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The funding will be used to advance SB-0110, a novel, proprietary small molecule with a unique mechanism of action that was identified using Sinopia’s LEADS™ platform, into Phase II clinical trials.

                          Brand Name : SB-0110

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 19, 2023

                          Lead Product(s) : SB-0110

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : NINDS

                          Deal Size : $3.3 million

                          Deal Type : Funding

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The funding will be used to advance SB-0110, a novel, proprietary small molecule with a unique mechanism of action that was identified using Sinopia’s LEADS™ platform, into Phase I clinical trials.

                          Brand Name : SB-0110

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 19, 2023

                          Lead Product(s) : SB-0110

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : MJFF

                          Deal Size : $2.0 million

                          Deal Type : Funding

                          blank